Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
新澤西州帕斯帕尼，2024年11月12日（全球新聞稿）-- Pacira BioSciences, Inc.（納斯達克：PCRX）今天宣佈將參加以下兩個醫療保健會議的分析師主導的爐邊聊天：
- Jefferies London Healthcare Conference on Tuesday, November 19th at 3:00PM GMT (10:00AM ET).
- 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 1:00PM ET.
- 傑富瑞倫敦醫療保健會議將於11月19日星期二下午3:00（美國東部時間上午10:00）舉行。
- 第36屆派傑投資醫療保健會議將於12月3日星期二下午1:00（美國東部時間）舉行。
Live audio of the events can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
可以通過訪問公司的官方網站的「活動」頁面（investor.pacira.com）來獲取活動的直播音頻。活動結束後的兩週內也將提供網絡廣播的重播。
About Pacira
Pacira BioSciences delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults, sciatic nerve block in the popliteal fossa in adults, and adductor canal block in adults for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit .
About Pacira
Pacira BioSciences 提供創新的非阿片鎮痛療法，以改變患者的生活。Pacira 有三種商業階段的非阿片治療：EXPAREL（布比卡因脂質體注射懸浮液），一種長效局部鎮痛劑，目前已獲批准用於侵入性、筋膜平面阻滯、成人頸叢臂神經阻滯、成人膝窩坐骨神經阻滯，以及成人用於手術後疼痛管理的內收管阻滯；ZILRETTA（三氟氯噻噸長效注射懸浮液），一種長效的關節內注射，適應於膝關節骨關節炎疼痛的管理；以及 ioverao，一種新穎的手持設備，通過將冷溫度的精準、控制劑量傳遞到目標神經，提供即時的長效無藥物疼痛控制。該公司還在推進 PCRX-201 的開發，這是一種新穎的局部給藥基因療法，具有治療大範圍常見疾病（如骨關節炎）的潛力。欲了解更多關於 Pacira 的信息，請訪問。
CONTACT: Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com
聯繫方式：公司聯繫人：
Pacira BioSciences, Inc.
克里斯蒂安·佩德蒂
(973) 254-4387
Christian.pedetti@pacira.com
